Pre-Exposure Prophylaxis (PrEP) Awareness Is Low Among Heterosexual People of Color Who Might Benefit From PrEP in Philadelphia

Alexis M. Roth¹, Nguyen K. Tran¹, Brogan L. Piecara¹, Jennifer Shinefeld², and Kathleen A. Brady²

Abstract
Introduction: We assessed awareness of pre-exposure prophylaxis (PrEP) among HIV-negative Black and Latinx persons living in the Philadelphia Metropolitan Statistical Area. Methods: Using chi-square and Wilcoxon rank-sum tests, we analyzed data from the 2016 heterosexual cycle of the National HIV Behavioral Surveillance system to assess how sociodemographic factors, health care utilization, and risk behaviors affected PrEP awareness. Results: Participants (n = 472) were predominantly Black, non-Hispanic (88.1%) with a median age of 41.5 years. Most participants reported having a usual source of medical care (92.1%) and seeing a medical provider within 12 months (87.0%). However, PrEP awareness was low in this sample (4.9%) and was lower among those who had a medical visit compared with those who had not (P < .01). Conclusion: Current Centers for Disease Control and Prevention clinical guidelines suggest that providers counsel high-risk patients about PrEP. Our data suggest that this is not happening with people of color in Philadelphia. Interventions targeting medical providers working with HIV-risk people of color may be appropriate.

Keywords
pre-exposure prophylaxis, HIV prevention, persons of color, patient-provider interactions, intervention

Introduction
In 2016, 25% of newly diagnosed HIV cases (n = 39,589) in the United States were attributable to heterosexual intercourse.¹ Nationwide, Pennsylvania ranked ninth in the number of new HIV diagnoses.¹ The majority of these HIV cases occurred in Philadelphia, where significant racial and ethnic disparities in incidence are observed among heterosexuals and by sex.² Of 162 newly diagnosed cases in Philadelphia among this group in 2016, 56.8% occurred among women and 86.4% occurred among Black and Latinx persons. Despite heterosexual intercourse being a substantial contributor to HIV burden among people of color (POC), there are stark racial and ethnic disparities in accessing biomedical prevention methods, such as pre-exposure prophylaxis (PrEP).³ This article estimates PrEP awareness, a critical determinant of PrEP seeking, among heterosexual POC participating in the 2016 cycle of the National HIV Behavioral Surveillance (NHBS) study in Philadelphia Metropolitan Statistical Area.

Methods
NHBS is conducted in 23 cities and territories to understand the HIV prevention needs of vulnerable populations in the United States. Recruitment methods are detailed elsewhere.¹ Briefly, a small number of seeds were incentivized to recruit members of their social and sexual networks as is typical in studies using respondent-driven sampling, a Markov chain recruitment method used to derive population-level estimates for hidden groups. Subsequent recruitment waves were conducted until the desired sample size was met. Participants received $25 for completing the study.

¹Drexel University, Philadelphia, PA, USA
²Philadelphia Department of Public Health, Philadelphia, PA, USA

Corresponding Author:
Alexis M. Roth, Department of Community Health and Prevention, Drexel University, 3215 Market Street, Room 435, Philadelphia, PA 19104, USA.
Email: alexisroth@drexel.edu
Institutional Review Boards approved by the City of Philadelphia and Drexel University conducted using SAS 9.4 (Cary, NC). Procedures were examined differences in accessing various types of health engagement, and PrEP awareness. Secondary analyses gender differences in HIV risk behaviors, health care and bivariable logistic regressions were used to assess prevention intervention, including talking with HIV

Less than 15% reported participating in some form of HIV (92.1%), and a medical visit within 12 months (87.0%). Currently insured (91.3%), had a usual source of health care Hispanic/Latinx ethnicity (see Table 1). Most were currently insured (91.3%), had a usual source of health care and were created using RDS Analyst (RDS-A) to adjust for recruitment (ie, due to homophily) and generate population-based estimates. χ² tests, Wilcoxon rank-sum tests, and bivariable logistic regressions were used to assess gender differences in HIV risk behaviors, health care engagement, and PrEP awareness. Secondary analyses examined differences in accessing various types of health care between persons PrEP aware (vs not). Analyses were conducted using SAS 9.4 (Cary, NC). Procedures were approved by the City of Philadelphia and Drexel University Institutional Review Boards.

Results

The sample was comprised of 472 POC, 88.1% identified as non-Hispanic Black; the remainder identified as Hispanic/Latinx ethnicity (see Table 1). Most were currently insured (91.3%), had a usual source of health care (92.1%), and a medical visit within 12 months (87.0%). Less than 15% reported participating in some form of HIV prevention intervention, including talking with HIV prevention professional or receiving free condoms despite 78% receiving an HIV test. Far fewer received an STI screen (47.7%) and 4.1% were positive for syphilis or gonorrhea, both of which have been linked to HIV acquisition among heterosexuals. Transactional sex in the past 12 months was reported by 8.3% of our sample. Noninjection drug use was reported by 38.5% of the sample; those reporting noninjection drug use had increased odds of being men (odds ratio [OR] 2.09; 95% CI 1.23-3.58) compared with nondrug users.

Overall, PrEP awareness was very low at 4.9% (95% CI 1.9% to 7.9%). PrEP awareness was lower among those who had a health care visit within the past 12 months compared with those who had not (OR 0.09; 95% CI 0.03-0.32) (see Table 2). PrEP awareness was also lower among those with a usual source of health care though this difference did not reach statistical significance (OR 0.41; 95% CI 0.06-2.61). The only health care variable associated with increased PrEP awareness was participation in an HIV prevention intervention (conversations with HIV prevention professional or receiving free condoms). Compared with those who had not participated, those who had participated were 5.53-fold more likely to be PrEP aware (95% CI 1.55-19.7). There was no statistical difference in PrEP awareness by gender, race/ethnicity, undergoing STI testing or receiving a diagnosis of STI positive (with gonorrhea or syphilis) within 12 months, or undergoing HIV testing within 12 months.

Discussion

Generally, PrEP awareness among heterosexual POC who participated in the 2016 Philadelphia NHBS was quite low and is lower than rates of awareness found in larger nationally representative studies. For example, the rate of PrEP awareness in our sample was 4.9%, which is much lower than found in a nationally representative sample of 855 Black individuals participating in an online survey in the same year (4.9% vs 14.5%). Furthermore, in this same comparator study, 19.8% of high-risk individuals knew about PrEP; however, in our study, high-risk behaviors were not significantly associated with PrEP awareness, which suggests additional efforts to educate Philadelphian POC are warranted.

Importantly, the approximately 15% of POC that engaged in in HIV prevention programming were significantly more likely to be PrEP aware which is encouraging. However, it is discouraging that engagement in medical care had no impact on PrEP awareness among the 87% of the sample who had a health care visit within 12 months, some of whom screened positive for an STI. CDC clinical guidelines suggest providers counsel their high-risk patients about PrEP. In this sample, the majority reported inconsistent condom use (85%), more than 2 sexual partners within
### Table 1. Demographic, HIV Risk Behaviors, Health Care Utilization Among POC Participants in the 2016 NHBS in Philadelphia (n = 472).

| Demographics | Total Unweighted No. (n = 472) | Total Weighted % (95% CI) | Male Weighted Row % (95% CI) | Female Weighted Row % (95% CI) | \(P^a\) | OR (95% CI) |
|--------------|---------------------------------|---------------------------|-----------------------------|-------------------------------|------|------------|
| Age, y, median (IQR) | 41.5 (27-50) | 42 (28-51) | 40 (26-50) | .34 | 1.00 (0.98, 1.02) |
| Gender | | | | | | |
| Male | 271 | 49.9 (42.5, 57.4) | 50.0 (43.4, 56.6) | 50.0 (43.4, 56.6) | 1.12 (0.36, 3.49) |
| Female | 201 | 50.1 (42.6, 57.5) | 50.0 (43.4, 56.6) | 50.0 (43.4, 56.6) | Ref |
| Race/Ethnicity | | | | | | |
| Black, non-Hispanic | 451 | 88.1 (80.7, 95.6) | 50.0 (43.4, 56.6) | 50.0 (43.4, 56.6) | 1.12 (0.36, 3.49) |
| Hispanic/Latinx | 21 | 11.9 (4.4, 19.3) | 47.2 (19.9, 75.9) | 52.8 (25.1, 80.5) | Ref |
| Education level | | | | | | |
| Less than high school | 129 | 33.9 (26.0, 41.7) | 49.3 (36.9, 61.7) | 50.7 (38.3, 63.1) | Ref |
| High school/GED | 274 | 53.4 (45.9, 61.0) | 53.6 (45.0, 62.2) | 46.4 (37.8, 55.0) | 1.19 (0.65, 2.17) |
| Some college or more | 69 | 12.7 (8.6, 16.4) | 35.4 (19.9, 51.0) | 64.6 (49.0, 80.1) | 0.57 (0.24, 1.31) |
| Below federal poverty level | | | | | | |
| Yes | 401 | 88.7 (84.8, 92.6) | 48.8 (41.8, 55.7) | 51.2 (44.3, 58.2) | 0.73 (0.33, 1.58) |
| No | 71 | 12.3 (8.4, 16.3) | 56.7 (38.8, 74.6) | 43.3 (25.4, 61.1) | Ref |
| Homeless, 12 mo | | | | | | |
| Yes | 64 | 12.6 (6.9, 18.2) | 56.6 (38.1, 75.1) | 43.4 (24.9, 61.9) | 1.36 (0.61, 3.04) |
| No | 408 | 87.4 (83.5, 91.5) | 48.9 (42.0, 55.8) | 51.1 (44.2, 58.0) | Ref |
| Health utilization and prevention services within 12 months | | | | | | |
| Currently insured | | | | | | |
| Yes | 412 | 91.3 (87.5, 95.1) | 46.0 (39.2, 52.8) | 54.0 (47.2, 60.8) | 0.18 (0.07, 0.48) |
| No | 51 | 8.7 (5.0, 12.4) | 82.2 (68.5, 95.9) | 17.8 (4.0, 31.5) | Ref |
| Have usual source of care | | | | | | |
| Yes | 436 | 92.1 (88.4, 95.8) | 48.4 (41.7, 55.1) | 51.6 (44.9, 58.3) | 0.51 (0.18, 1.42) |
| No | 36 | 7.9 (4.1, 11.7) | 65.0 (42.3, 87.7) | 35.0 (12.3, 57.7) | Ref |
| Health care visit, 12 mo | | | | | | |
| Yes | 404 | 87.0 (82.6, 91.4) | 46.0 (39.1, 52.9) | 54.0 (47.1, 60.9) | 0.31 (0.13, 0.74) |
| No | 68 | 13.0 (8.5, 17.5) | 73.2 (57.1, 89.4) | 26.8 (10.6, 42.9) | Ref |
| STI test, 12 mo | | | | | | |
| Yes | 222 | 47.7 (40.2, 55.1) | 39.3 (30.2, 48.5) | 60.7 (51.5, 69.8) | 0.44 (0.26, 0.75) |
| No | 248 | 52.3 (45.8, 58.7) | 59.5 (50.7, 68.4) | 40.5 (31.6, 49.3) | Ref |
| HIV test, 12 mo | | | | | | |
| Yes | 348 | 76.7 (71.3, 82.0) | 51.5 (44.0, 59.0) | 48.5 (41.0, 56.0) | 1.35 (0.75, 2.43) |
| No | 124 | 23.3 (18.0, 28.6) | 44.1 (41.6, 56.6) | 55.9 (43.4, 68.4) | Ref |
| Participation in HIV prevention intervention, 12 mo<sup>b</sup> | | | | | | |
| Yes | 86 | 14.2 (9.7, 18.7) | 49.9 (42.8, 57.0) | 50.1 (43.0, 57.2) | 1.07 (0.47, 2.09) |
| No | 386 | 85.8 (81.4, 90.4) | 49.3 (33.4, 65.2) | 50.7 (34.8, 66.6) | Ref |
| HIV risk behaviors within 12 months | | | | | | |
| Condomless vaginal or anal sex | | | | | | |
| Yes | 407 | 85.0 (79.8, 90.3) | 49.0 (42.0, 55.9) | 51.0 (44.1, 58.0) | 0.80 (0.98, 1.70) |
| No | 65 | 15.0 (10.4, 20.0) | 54.4 (37.0, 71.8) | 45.6 (28.2, 62.9) | Ref |
| Sex with 2+ partners | | | | | | |
| Yes | 296 | 55.8 (48.4, 63.3) | 59.5 (51.2, 67.9) | 40.4 (32.1, 48.8) | 2.45 (1.44, 4.21) |
| No | 171 | 44.2 (37.6, 50.5) | 40.5 (32.1, 48.8) | 59.5 (48.2, 72.2) | Ref |
| STI diagnosis<sup>c</sup> | | | | | | |
| Yes | 21 | 4.1 (1.8, 6.4) | 52.1 (31.8, 72.3) | 47.9 (27.7, 68.2) | 1.11 (0.47, 2.60) |
| No | 451 | 95.9 (92.0, 98.7) | 49.6 (42.7, 56.4) | 50.4 (43.6, 57.3) | Ref |

(continued)
Table 1. (continued)

|                          | Total Unweighted No. (n = 472) | Total Weighted % (95% CI) | Male Weighted Row % (95% CI) | Female Weighted Row % (95% CI) | P  | OR (95% CI) |
|--------------------------|--------------------------------|----------------------------|-------------------------------|-------------------------------|----|-------------|
| **Transactional sex**    |                                |                            |                               |                               |    |             |
| Yes                      | 54                             | 8.8 (3.2, 13.3)            | 57.3 (36.6, 78.1)             | 42.7 (21.9, 63.4)             | .73 |             |
| No                       | 418                            | 91.7 (89.1, 94.6)          | 49.2 (42.4, 56.0)             | 50.8 (43.9, 57.6)             |    | 1.39 (0.57, 3.37) |
| **Any illicit noninjection drug use** |                      |                            |                               |                               | <.01 |             |
| Yes                      | 211                            | 38.5 (31.5, 45.5)          | 60.7 (50.7, 70.7)             | 39.3 (29.3, 49.3)             |    | 2.09 (1.23, 3.58) |
| No                       | 261                            | 61.5 (55.5, 68.2)          | 39.3 (34.3, 50.6)             | 57.5 (49.4, 65.7)             |    | Ref         |
| **Binge alcohol use**    |                                |                            |                               |                               | .78 |             |
| Yes                      | 93                             | 14.1 (9.8, 18.4)           | 51.8 (36.2, 67.4)             | 48.2 (32.6, 63.8)             |    | 1.10 (0.43, 1.98) |
| No                       | 379                            | 85.9 (81.2, 90.1)          | 49.4 (42.3, 56.5)             | 50.6 (43.3, 57.7)             |    | Ref         |
| **PrEP**                 |                                |                            |                               |                               | .08 |             |
| PrEP awareness           |                                |                            |                               |                               |    |             |
| Yes                      | 21                             | 4.9 (1.9, 7.9)             | 72.5 (48.9, 95.9)             | 27.5 (4.0, 51.1)              |    | 2.79 (0.36, 2.12) |
| No                       | 451                            | 95.1 (91.7, 97.9)          | 48.5 (41.9, 55.1)             | 51.5 (44.9, 58.1)             |    | Ref         |

**Abbreviations:** POC, people of color; NHBS, National HIV Behavioral Surveillance; CI, confidence interval; OR, odds ratio; IQR, interquartile range; Ref, reference; STI, sexually transmitted infection; PrEP, pre-exposure prophylaxis.

*P value based on χ² test or Wilcoxon rank-sum test.

bIncludes talking to HIV prevention professional or receiving free condoms.

cIncludes only syphilis and gonorrhea for this analysis.

Table 2. Health Care Utilization by PrEP Awareness Among POC Participants in the 2016 NHBS in Philadelphia (n = 472).

|                          | PrEP Aware Weighted Row % (95% CI) | PrEP Unaware Weighted Row % (95% CI) | P  | OR (95% CI) |
|--------------------------|-----------------------------------|--------------------------------------|----|-------------|
| Have usual source of care|                                    |                                      |    |             |
| Yes                      | 4.7 (1.5, 7.7)                    | 95.3 (92.3, 98.3)                    | .32| 0.41 (0.06, 2.61) |
| No                       | 10.8 (0.01, 27.7)                 | 89.2 (72.4, 100)                     |    | Ref         |
| Health care visit, 12 mo |                                    |                                      |    |             |
| Yes                      | 2.5 (0.9, 4.3)                    | 97.5 (95.7, 99.2)                    | <.01|                |
| No                       | 21.7 (4.9, 38.6)                  | 78.3 (61.4, 95.1)                    |    | Ref         |
| STI test, 12 mo          |                                    |                                      |    |             |
| Yes                      | 5.3 (1.0, 9.6)                    | 94.7 (90.4, 98.9)                    | .95| 1.04 (0.30, 3.61) |
| No                       | 5.1 (0.7, 9.6)                    | 94.9 (90.5, 99.3)                    |    | Ref         |
| HIV test, 12 mo          |                                    |                                      |    |             |
| Yes                      | 5.0 (1.6, 8.5)                    | 95.0 (91.5, 98.4)                    | .84| 0.86 (0.20, 3.65) |
| No                       | 5.8 (0.01, 12.7)                  | 94.2 (87.3, 100)                    |    | Ref         |
| Participation in HIV prevention intervention, 12 mo | | | | |
| Yes                      | 15.9 (3.6, 28.2)                  | 84.1 (71.7, 96.4)                    | <.01|                |
| No                       | 3.3 (0.5, 6.1)                    | 96.7 (93.9, 99.5)                    |    | Ref         |

**Abbreviations:** POC, people of color; NHBS, National HIV Behavioral Surveillance; CI, confidence interval; OR, odds ratio; Ref, reference; STI, sexually transmitted infection; PrEP, pre-exposure prophylaxis.

*P value based on χ² test or Wilcoxon rank-sum test.

Includes talking to HIV prevention professional or receiving free condoms.

12 months (55.8%), and higher than population-level estimates for HIV-related risk behaviors (ie, STI rates in our sample [4.1%] vs national adult prevalence estimates [1.6%]). This suggests 2 important findings. First, heterosexual POC in Philadelphia would benefit from being educated about PrEP in order to increase awareness about this safe, effective, and underutilized HIV prevention modality. Second, there is a disconnect between providers and POC patients when it comes to taking a sexual history, disclosing HIV risk behavior, and/or estimating HIV risk.

Failure to assess risk may be the result of providers being unaware of PrEP and relevant clinical guidelines,
their discomfort with prescribing PrEP and with taking sexual history, or having biases that result in a lower likelihood to prescribe PrEP to heterosexual POC. Studies have found that biases based on race and sexual orientation have an impact on provider willingness to prescribe PrEP. Alternatively, it could be that patients are not disclosing HIV risk to providers. Medical mistrust, stemming from a long history of medical abuse and experimentation on Black Americans, has been well documented. Ball et al suggest that medical mistrust in the form of conspiracy beliefs directly affect Black Americans' willingness to engage in HIV preventive behavior (ie, condom use) and treatment. Limited research has focused on medical mistrust and PrEP among heterosexuals. However, a recent study among Black men who have sex with men suggests that medical mistrust may affect PrEP willingness and uptake.

Our findings must be interpreted within the limitations of the study design. First, we relied on self-reported data with 12-month recall which are subject to social desirability and recall biases. Second, NHBS does not specifically assess patient-provider conversations about PrEP or HIV risk behavior during health care visits. We may have overestimated the missed opportunity for these conversations to occur. Third, RDS is subject to 2 main sources of bias: differential network size (eg, people are connected to networks of different sizes therefore smaller networks may be underrepresented) and nonindependence (eg, homophily or people's tendency to belong to networks demographically similar to themselves). To account for these biases, we applied sampling weights generated from RDS-A. Fourth, our study may be underpowered because of its sample size. Finally, NHBS does not measure medical mistrust so this may not be a factor in this population. Future iterations of the NHBS could collect these data to further tease apart these relationships.

Our findings suggest PrEP messaging is not reaching heterosexual POC in Philadelphia. Using Centers for Disease Control and Prevention methods, we estimate there are over 3300 heterosexuals in Philadelphia who have a PrEP indication, of whom 78% are Black and 15% are Latinx compared with 4% who are White. Given this, it seems that additional PrEP promotional efforts tailored to heterosexual POC are warranted. A recent cost effectiveness study indicated that primary prevention interventions for heterosexuals are best suited to primary care settings. Thus, interventions that encourage providers to follow PrEP guidelines with patients of color are encouraged.

Acknowledgments

We would like to thank the staff at the Philadelphia Department of Public Health who were involved in data collection, including Nicole Bundy, Rafael Melecio, Dolicia Dobbs, and Jen Shinefeld.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded through a cooperative agreement between the Philadelphia Health Department, AIDS Activities Coordinating Office, and the Centers for Disease Control and Prevention, 6NU62PS005088. Support for Dr Roth and N. K. Tran was provided through a career development award from the American Sexually Transmitted Diseases Association.

ORCID iD

Brogan L. Piecara https://orcid.org/0000-0001-8099-4399

References

1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2017. Vol 29. Atlanta, GA: US Department of Health and Human Services; 2018.
2. Philadelphia Department of Public Health. AIDS Activities Coordinating Office Surveillance Report, 2016. Philadelphia, PA: City of Philadelphia; 2017.
3. Mera Giler R, Trevor H, Bush S, Rawlings K, McCallister S, eds. Changes in truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: (2012-2016). Paper presented at: 9th International AIDS Society Conference on HIV Science; July 23-26, 2017; Paris, France.
4. Gallagher KM, Sullivan PS, Lansky A, Onorato IM. Behavioral surveillance among people at risk for HIV infection in the US: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122(suppl 1):32-38.
5. Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14:40.
6. Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDs. 2010;24:689-691.
7. Young I, Li J, McDaid L. Awareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV prevention. PloS One. 2013;8:e64038.
8. Yi S, Tuot S, Mwai GW, et al. Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low-and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc. 2017;20:21580.
9. Ojikutu BO, Bogart LM, Higgins-Biddle M, et al. Facilitators and barriers to pre-exposure prophylaxis (PrEP) use among black individuals in the United States: results from the National Survey on HIV in the Black Community (NSHBC). AIDS Behav. 2018;22:3576-3587.
10. Centers for Disease Control and Prevention. US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. Accessed April 19, 2019.

11. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187-193.

12. Bull SS, Rietmeijer C, Fortenberry DJ, Stoner B, Malotte K, Vandenbunter N, et al. Practice patterns for the elicitation of sexual history, education, and counseling among providers of STD services: results from the Gonorrhea Community Action Project (GCAP). Sex Transm Dis. 1999;26:584-588.

13. Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21:1256-1267.

14. Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav. 2014;18:226-240.

15. Ball K, Lawson W, Alim T. Medical mistrust, conspiracy beliefs & HIV related behavior among African Americans. J Psychol Behav Sci. 2013;1:1-7.

16. Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29:1351-1358.

17. Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28:850-857.e9.

18. Yaylali E, Farnham PG, Cohen S, Purcell DW, Hauck H, Sansom SL. Optimal allocation of HIV prevention funds for state health departments. PLoS One. 2018;13:e0197421.

Author Biographies

Alexis M. Roth, PhD, MPH, is a behavioral scientist with expertise in substance use and infectious disease. She is an Assistant Professor in the Department of Community Health and Prevention at the Dornsife School of Public Health at Drexel University.

Nguyen K. Tran, MPH is a doctoral student in the Department of Epidemiology and Biostatistics. His research interests include infectious disease epidemiology (with specific interests in HIV and bacterial STIs) and epidemiologic methods.

Brogan L. Piecara, MPH is a project manager in the Department of Community Health and Prevention at the Dornsife School of Public Health. She has managed and worked on projects related to sexual health, substance use, HIV prevention, and overdose prevention among vulnerable populations since 2015.

Jennifer Shinefeld, MS is the project coordinator & co-principal investigator at Philadelphia Department of Public Health (PDPH), AIDS Activities Coordinating Office (AACO). Since 2013, she has conducted epidemiologic and quality of care analyses in HIV using public health surveillance data to evaluate population-level outcomes and interventions along the HIV Prevention and Care Continuum.

Kathleen A. Brady, MD is the Medical Director and Medical epidemiologist at Philadelphia Department of Public Health (PDPH), AIDS Activities Coordinating Office (AACO). Since 1999, she has conducted epidemiologic and quality of care analyses in HIV using public health surveillance data to evaluate population-level outcomes and interventions along the HIV Prevention and Care Continuum.